Active	Status	Sponsor type	Region	Phase	Filter
2 Active 4 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ecleralimab (CSJ117) / Novartis
2021-000692-36: Study of effect of CSJ117 on symptoms, pharmacodynamics and safety in patients with COPD	Ongoing	2	300	Europe	CSJ117, Inhalation powder, hard capsule	Novartis Pharma AG, Novartis Pharma AG	Chronic Obstructive Pulmonary Disease, COPD, Diseases [C] - Respiratory Tract Diseases [C08]
2020-002341-42: Study of safety of CSJ117 in participants with moderate to severe uncontrolled asthma	Ongoing	2	375	RoW, Europe	CSJ117, Inhalation powder, hard capsule	Novartis Pharma AG, Novartis Pharma AG	Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]